pipette
ESEspañol

RETRO-URETERAL DELIVERY OF AAV-KP VECTORS FOR RENAL GENE TRANSFER AND THE ASSESSMENT OF TRANSGENE REABSORPTION IN THE KIDNEY

S. Milagros, N. Santana-Gonzalez, M. Bilbao, L. Neri, B. Carte, A. Vales, M. Mendez, L. Lisowski, N. Zabaleta, G. Gonzalez-Aseguinolaza, R. Aldabe

Preprint

In the authors' words

Monogenic disorders cause a substantial fraction of chronic kidney disease, yet no renal gene therapy exists, partly because adeno-associated virus (AAV) vectors transduce the kidney poorly after systemic delivery. Screening a barcoded library of 80 natural and chimeric AAV serotypes administered retrogradely into the mouse renal pelvis identified AAV-KP1, AAV-KP2 and AAV-KP3 as enriched in the injected kidney but not in the liver. Individual validation confirmed efficient transduction of the administered kidney, with vector genome copy numbers approaching hepatic levels, 50- to 500-fold above the contralateral kidney and far above AAV9. Using kidney-specific (KSPC) and ubiquitous (CMV) promoters, transduction was detected in collecting duct, distal convoluted tubule, proximal tubule, Bowman's capsule, interstitial cells and podocytes, with cell-type coverage depending on the promoter. Unexpectedly, GFP and mCherry protein was abundant in proximal tubules of kidneys lacking transgene mRNA, including contralateral and intravenously dosed kidneys. RNA-FISH, vector genome quantification and serum mCherry indicate that this protein derives from circulating transgene product filtered and reabsorbed by the proximal tubule rather than from local transduction. Retrograde delivery of AAV-KP capsids therefore achieves broad renal epithelial transduction, and transgene mRNA must be assessed alongside protein if kidney-tropic capsids are to be ranked reliably.

Main resultLimitation the authors admit

Appeared: Thursday, November 19. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.18.767076